New research suggests that people who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who halt conventional diet and exercise plans.
Research printed in a prominent health publication points out that while overweight individuals frequently drop a large proportion of their total mass while on the medication, the mass is regained at an estimated rate of nearly a kilo each month after stopping.
"People using these treatments must be aware of the danger of fast weight regain when the medication ends," stated researcher Dr. Susan Jebb.
This pace of recovery suggests a reversion to original mass in about 18 months.
Analyzing Treatments
The analysis, which looked at dozens of studies involving over 9,000 of patients, contrasted the results of the injectable medications with other pills.
Researchers point out that individuals who lose weight through lifestyle changes alone generally experience a less rapid creep back—approximately 100 grams monthly—once they finish.
Explaining the Rapid Rebound
Nutrition scientists believe the mechanism of the drugs accounts for the amplified weight return.
These medications imitate a body's own chemical called GLP-1, which moderates feelings of fullness.
"Artificially providing the hormone levels far above than the body's typical production could lead to the body to produce less of its endogenous hormone, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' leads to appetite is unsuppressed, making overeating far more likely."
A Lifelong Disease?
The NHS advise the injections for people with weight-linked health risks, alongside recommended diet and exercise modifications.
Many experts argue that, given the likelihood of relapse, the treatment should be considered ongoing.
This opinion is echoed by pharmaceutical companies, who state that the findings "emphasize the chronic nature of obesity," comparing it to managing diseases like hypertension.
Patient Experiences
People who have stopped the medication describe a intense resurgence of hunger.
"It felt as if something activating and you become extremely hungry," described one woman.
The struggle is compounded if users have not established permanent dietary or behavioural modifications during therapy.
Growing Adoption
Survey data show that millions of people in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.
- Use is higher among women compared to men.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, experts emphasize that while the jabs are powerful tools for weight loss, they are not a standalone fix and maintained weight loss relies on ongoing behavioural support.
